Xencor, Inc. (XNCR)

Add to research

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Company performance
Add to research
View more

Current Price

as of Mar 14, 2025

$12.76

P/E Ratio

N/A

Market Cap

$899.09M

Loading...
Description
Add to research
View more

Xencor, Inc. is a biopharmaceutical company, which engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. Its proprietary technology platform, XmAb, is used to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions. The company was founded by Bassil I. Dahiyat and Stephen L. Mayo in August 1997 and is headquartered in Monrovia, CA.

Metrics
Add to research
View more

Overview

  • HQPasadena, CA
  • SectorHealth Technology
  • IndustryBiotechnology
  • TickerXNCR
  • Price$12.76-0.85%

Trading Information

  • Market cap$899.09M
  • Float93.81%
  • Average Daily Volume (1m)614,203
  • Average Daily Volume (3m)625,514
  • EPS-$3.58

Company

  • Revenue$110.49M
  • Rev growth (1yr)-36.72%
  • Net income-$232.62M
  • Gross margin89.04%
  • EBITDA margin-150.51%
  • EBITDA-$166.30M
  • EV$1.23B
  • EV/Revenue11.09
  • P/EN/A
  • P/S7.51
  • P/B1.32
  • Debt/Equity34.23
Documents
Add to research
View more